Open Up a World

More than 500,000 asthma patients received 2 or more OCS bursts last year1

GINA guidelines state that maintenance OCS use should be the last
resort for asthma treatment because it can lead to side effects2:

POTENTial Short-term side effects


Increased risk of fracture



POTENTial Long-term side effects




This is not an exhaustive list of all potential side effects associated with OCS.

DUPIXENT is the only FDA-approved biologic indicated for OCS-dependent asthma patients3

Two or more steroid bursts in the past year
may be a sign of uncontrolled asthma2,4

DUPIXENT reduced or eliminated OCS use and improved more than one measure of asthma control3,5

DUPIXENT reduced or eliminated steroids while simultaneously improving asthma control3,5

of patients reduced or eliminated their OCS dose5,a
reduction was observed in severe exacerbations3,b
220 mL
improvement was seen in lung function5,c

No biomarker requirement, ITT population: Reduced or eliminated OCS dose and reduced severe exacerbation rates and improved lung function (secondary endpoints) at Week 243,5,d-f

  • Effects on lung function and on oral steroid and exacerbation reduction were similar irrespective of baseline blood eosinophil levels. Subjects with baseline blood eosinophil levels up to 1500 cells/μL were included3
  • 70% significant reduction in OCS dose (median 100%) from baseline at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103)
    (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint)3

a At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) in VENTURE.5

b At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs placebo + SOC (n=107) (0.65 vs 1.60; rate ratio: 0.41 [95% CI: 0.26, 0.63]) in VENTURE.3

c At Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 10 mL with placebo + SOC (n=107) (LSM difference: 220 mL [95% CI: 90, 340 mL]) in VENTURE.5

d ITT population was unrestricted by minimum baseline eosinophils or other type 2 biomarkers (eg, FeNO or IgE).5

e The baseline mean OCS dose was 12 mg in the placebo group and 11 mg in the group receiving DUPIXENT.3

f Asthma exacerbation was defined as a temporary increase in OCS dose for at least 3 days.3

No biomarker testing required for 99% of OCS-dependent asthma patients who are commercially insured7

FeNO, fractional exhaled nitric oxide; GINA, Global Initiative for Asthma; ITT, intention-to-treat; LSM, least squares mean; OCS, oral corticosteroid; Q2W, once every 2 weeks; SOC, standard of care.


of patients from VENTURE eliminated their OCS dose for up to ~3 years

A gradual increase in the number of patients eliminating their OCS dose was observed from 53.3% at Week 0 (n=48) to 59.6% at Week 48 (n=34) to 78.9% at Week 96 (n=15) in the DUPIXENT/DUPIXENT group (TRAVERSE OLE study, secondary endpoint)6,g

Results are descriptive. Definitive conclusions cannot be made.

Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm,
decreasing sample size, and potential continued involvement of responders and attrition of non-responders.

gOCS reduction was at investigators’ discretion.6

No biomarker testing required for 99% of OCS-dependent asthma patients who are commercially insured7

OCS, oral corticosteroid; OLE, open-label extension.